Evidence map›Paper›PMID 34354145›Full record

ArticleScientific reports2021

Yippee like 4 (Ypel4) is essential for normal mouse red blood cell membrane integrity.

Alexander Mattebo, Taha Sen, Maria Jassinskaja, Kristýna Pimková, Isabel Prieto González-Albo, Abdul Ghani Alattar, Ramprasad Ramakrishnan, Stefan Lang, Marcus Järås, Jenny Hansson and 4 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. The YPEL genePlant signaling & behavior · 2026
    Article
  2. Whole Blood Transcriptomic Analysis of Sickle Cell Trait.European journal of haematology · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 2 countries.

Alexander MatteboDivision of Molecular Medicine and Gene Therapy, Lund Stem Cell Center, Lund University, Lund, Sweden.
Taha SenDivision of Molecular Medicine and Gene Therapy, Lund Stem Cell Center, Lund University, Lund, Sweden.
Maria JassinskajaDivision of Molecular Hematology, Lund Stem Cell Center, Lund University, Lund, Sweden.
Kristýna PimkováDivision of Molecular Hematology, Lund Stem Cell Center, Lund University, Lund, Sweden.
Isabel Prieto González-AlboDivision of Molecular Medicine and Gene Therapy, Lund Stem Cell Center, Lund University, Lund, Sweden.
Abdul Ghani AlattarDivision of Molecular Medicine and Gene Therapy, Lund Stem Cell Center, Lund University, Lund, Sweden.
Ramprasad RamakrishnanDivision of Clinical Genetics, Faculty of Medicine, Lund University, Lund, Sweden.
Stefan LangDivision of Molecular Hematology, Lund Stem Cell Center, Lund University, Lund, Sweden.
Marcus JäråsDivision of Clinical Genetics, Faculty of Medicine, Lund University, Lund, Sweden.
Jenny HanssonDivision of Molecular Hematology, Lund Stem Cell Center, Lund University, Lund, Sweden.
Shamit SonejiDivision of Molecular Hematology, Lund Stem Cell Center, Lund University, Lund, Sweden.
Sofie SingbrantDivision of Molecular Medicine and Gene Therapy, Lund Stem Cell Center, Lund University, Lund, Sweden.
Emile van den AkkerSanquin Research, Department of Hematopoiesis and Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Johan FlygareDivision of Molecular Medicine and Gene Therapy, Lund Stem Cell Center, Lund University, Lund, Sweden. johan.flygare@med.lu.se.
Lund University · SESanquin · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The YPEL family genes are highly conserved across a diverse range of eukaryotic organisms and thus potentially involved in essential cellular processes. Ypel4, one of five YPEL family gene orthologs in mouse and human, is highly and specifically expressed in late terminal erythroid differentiation (TED). In this study, we investigated the role of Ypel4 in murine erythropoiesis, providing for the first time an in-depth description of a Ypel4-null phenotype in vivo. We demonstrated that the Ypel4-null mice displayed a secondary polycythemia with macro- and reticulocytosis. While lack of Ypel4 did not affect steady-state TED in the bone marrow or spleen, the anemia-recovering capacity of Ypel4-null cells was diminished. Furthermore, Ypel4-null red blood cells (RBC) were cleared from the circulation at an increased rate, demonstrating an intrinsic defect of RBCs. Scanning electron micrographs revealed an ovalocytic morphology of Ypel4-null RBCs and functional testing confirmed reduced deformability. Even though Band 3 protein levels were shown to be reduced in Ypel4-null RBC membranes, we could not find support for a physical interaction between YPEL4 and the Band 3 protein. In conclusion, our findings provide crucial insights into the role of Ypel4 in preserving normal red cell membrane integrity.

Indexed as

AnemiaAnimalsAnion Exchange Protein 1, ErythrocyteCarrier ProteinsErythrocyte MembraneErythrocytesErythrocytes, AbnormalErythropoiesisFemaleMaleMiceMice, Inbred C57BLMice, KnockoutPolycythemiaSpleenAnion Exchange Protein 1, ErythrocyteCarrier ProteinsYPEL4 protein, human

Identifiers

PMID34354145
PMCPMC8342551
OpenAlexW3188534887

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.